Opens.
Delivers.
Maintains.
NEWS ALERT:
- May 2013:Why Intersect ENT is an Example of Hope for the Medtech Industry
- Mar 2013:Sinus “Stent” Helps Patients Breathe Easier
- Jan 2013:Warren Man With Chronic Sinusitus Breathes Easy After Implant Surgery
- Jan 2013:Intersect ENT Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients
- May 2013:Why Intersect ENT is an Example of Hope for the Medtech Industry
- Mar 2013:Sinus “Stent” Helps Patients Breathe Easier
- Jan 2013:Warren Man With Chronic Sinusitus Breathes Easy After Implant Surgery
- Jan 2013:Intersect ENT Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients
Company
Board of Directors
| Director | Company/Firm |
| Lisa Earnhardt | Intersect ENT |
| Mark Fletcher | Medtronic, Inc. |
| Dana Mead | Kleiner Perkins Caufield & Byers |
| Rick Anderson | PTV Sciences |
| Fred Moll, MD | Restoration Robotics |
| Casey Tansey | U.S. Venture Partners |
| Casper de Clercq | Norwest Venture Partners |
Investors
News & Events
Publications
Kennedy DW.
The PROPEL steroid releasing bioabsorbable implant to improve outcomes of sinus surgery.
Expert Review of Respiratory Medicine. 2012; 6(5):493-498.
Han JK, Marple BF, Smith TL et al.
Effect of steroid-releasing sinus implants on post-operative medical and surgical interventions.
Int Forum Allergy Rhinol. 2012; 2:271-279.